Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS semaglutide diabetic retinopathy outcomes study
2023-506827-26-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Presence of at least 3-step ETDRS subject-level progression at year 5. Planned start May 2019; status: authorised.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-506827-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506827-26-00.